Form 8-K - Current report:
SEC Accession No. 0001683168-25-005284
Filing Date
2025-07-22
Accepted
2025-07-22 16:39:58
Documents
16
Period of Report
2025-07-17
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 54445
2 CERTIFICATE OF CHANGE cns_ex0301.htm EX-3.1 811
3 PRESS RELEASE DATED JULY 18, 2025 cns_ex9901.htm EX-99.1 8271
4 GRAPHIC image_003.jpg GRAPHIC 223334
5 GRAPHIC image_001.jpg GRAPHIC 4558
  Complete submission text file 0001683168-25-005284.txt   550864

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20250717.xsd EX-101.SCH 3017
7 XBRL LABEL FILE cnsp-20250717_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE cnsp-20250717_pre.xml EX-101.PRE 22360
18 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3805
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 251140729
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)